Tag Archive for: Asceneuron

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]

Optimum TV launches amid green shoots from the biotech markets 

The nights are getting shorter and the green shoots of spring are emerging – and it’s an exciting time for Optimum Strategic Communications as it launches Optimum TV! Our associate director and former national newspaper journalist Stephen Adams will be presenting regular YouTube episodes showcasing our clients’ amazing work.    Heidelberg grabs orphan designation  Heidelberg […]

Optimum’s clients build momentum in March

Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

• Further strengthening of leadership team following the appointment of industry stalwart Barbara Angehrn Pavik as Chief Executive Officer • Accelerating advancement of novel treatments to halt disease progression in neurodegenerative diseases Lausanne, SWITZERLAND and San Francisco, CA, USA, 18 December 2023 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root […]